Investor Alert: Sionna Therapeutics Faces Securities Fraud Investigation
Pomerantz Law Firm is investigating potential securities fraud or other unlawful business practices by Sionna Therapeutics, Inc. (NASDAQ: SION) and certain of its officers and directors on behalf of investors. The investigation follows a significant drop in the company's stock price after it announced that one of its clinical trials failed to meet key endpoints. On August 10, 2026, Sionna reported top-line data from two programs involving NBD1 stabilizers but revealed that the PreciSION CF Phase 2a trial for SION-719 did not achieve its primary endpoint of reducing sweat chloride levels in cystic fibrosis patients. This news led to a sharp decline in stock price, falling $46.54 per share or 91.18%. Pomerantz LLP is urging affected investors to contact the firm for potential class action participation.
Tickers: $SION
Topics: clinical trial results securities fraud stock price drop